Skip to main content
Premium Trial:

Request an Annual Quote

Kapa Biosystems Extends Distribution Pact with Nippon Genetics

NEW YORK (GenomeWeb) — Kapa Biosystems said today that it has signed a three-year exclusive distribution agreement with Nippon Genetics.

The agreement extends an existing seven-year relationship between the companies and enables Nippon to continue marketing, distributing, and servicing Kapa's genomics reagents in Japan.

Kapa, based in Wilmington, Mass., sells reagents for use in PCR, qPCR, next-generation sequencing, and molecular diagnostics. Nippon is headquartered in Tokyo and provides a range of genomic and molecular biology research products for applications such as nucleic acid separation and purification, electrophoresis, PCR, real-time PCR, and NGS library prep.

"We are seeing broad adoption and strong demand for our innovative products not only in Japan, but across the Asia Pacific, European, and North American regions," Jean-Christophe Hatinguais, director of international sales at Kapa Biosystems, said in a statement. "We are now focused on extending our global reach by increasing our strategic investments and expanding our distribution network in key markets."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.